Lacosamide Glenmark

Lacosamide, the active ingredient in Lacosamide Glenmark, is an anti‑epileptic presented as an oral tablet for oral use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑seizure medication used in the management of focal epilepsy and related conditions.

- Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. - Adjunctive therapy for epilepsy: improves overall seizure control in patients not fully controlled by other drugs. - Focal epilepsy: provides additional seizure reduction as part of combination therapy.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate stomach upset. - Headache: occasional throbbing pain. - Fatigue: feeling unusually tired. - Blurred vision: temporary visual disturbance. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Severe allergic reactions: anaphylaxis or angioedema. - Hepatic injury: signs of liver dysfunction including jaundice.

When prescribing lacosamide, clinicians should consider several safety aspects.

- Renal impairment: adjust dose based on renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: risk unknown; use only if potential benefit justifies the risk. - Concomitant sodium‑channel blockers: may increase central nervous system effects. - Store at below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with a variety of medicines, requiring careful management.

Major Interactions (Avoid): - Other sodium‑channel antiepileptics (e.g., carbamazepine, phenytoin): may increase toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce lacosamide effectiveness.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Other antiepileptic drugs (e.g., valproate): may require dose adjustments. - Anticoagulants (e.g., warfarin): may alter INR and bleeding risk.